Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, February 19th.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
Other equities research analysts have also recently issued research reports about the company. BidaskClub upgraded Aurinia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a report on Monday, October 30th. Cantor Fitzgerald restated a “buy” rating and set a $14.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. Royal Bank of Canada started coverage on Aurinia Pharmaceuticals in a report on Thursday, February 8th. They set an “outperform” rating and a $9.00 price objective on the stock. Finally, Canaccord Genuity set a $11.00 price objective on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $10.59.
A number of institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. boosted its holdings in Aurinia Pharmaceuticals by 33.2% in the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock valued at $7,540,000 after acquiring an additional 414,400 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Aurinia Pharmaceuticals by 36.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock valued at $5,411,000 after purchasing an additional 319,639 shares during the period. BlackRock Inc. purchased a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $3,261,000. Alyeska Investment Group L.P. raised its position in Aurinia Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after purchasing an additional 12,171 shares during the period. Finally, Hudson Bay Capital Management LP raised its position in Aurinia Pharmaceuticals by 20.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $2,039,000 after purchasing an additional 75,000 shares during the period. Hedge funds and other institutional investors own 28.50% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.